Objectives: To report insidious development of autonomic dysreflexia and hydronephrosis due to dyssynergic voiding following discontinuation of intrathecal baclofen therapy. Setting: Regional Spinal ...
Intrathecal baclofen (ITB) therapy is an established treatment for severe refractory spasticity. Although a positive ITB ...
Intrathecal baclofen (ITB) therapy has evolved into a standard treatment for severe spasticity. After this therapy had been provided for 10 years, a retrospective chart review on 50 patients, ...
September 14, 2012 — The US Food and Drug Administration (FDA) has approved a new catheter (Ascenda, Medtronic Inc) for use in the delivery of intrathecal baclofen (ITB) therapy. According to the ...
Researchers from Kessler Foundation and Kessler Institute for Rehabilitation (collectively termed "Kessler") have conducted the first prospective study to assess whether transcutaneous spinal ...
Intrathecal baclofen pumps treat lower-limb spasticity, and are mainly used for people with multiple sclerosis, cerebral palsy, or spinal cord injury1 Intrathecal baclofen (ITB) pumps implanted in the ...
Baclofen (Gablofen, Lioresal, Ozobax) is a medication that treats stiff muscles and spasms, a condition called spasticity, that can happen to people with multiple sclerosis (MS) and other nerve ...
Researchers from Kessler Foundation and Kessler Institute for Rehabilitation (collectively "Kessler") conducted the first prospective study to assess whether transcutaneous spinal stimulation (TSS) ...
ST. PAUL, Minn.--(BUSINESS WIRE)-- Today, CNS Therapeutics announced the FDA approval of Gablofen® (baclofen injection) for use in the management of severe spasticity, giving healthcare providers a ...
The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results